Dermal Filler News
Portland, OR — June 24, 2026 | By Cosmetiq Medicine
A new hyaluronic acid filler designed specifically for mid-face volume loss is now under FDA review, after its maker reported trial results that came in stronger than one of the most widely used fillers on the market today. If approved on schedule, Evolysse Sculpt could become commercially available by early 2027 — making it worth knowing about now, even before it’s an option you can book.
What Evolysse Sculpt actually is
Evolysse Sculpt is a hyaluronic acid (HA) gel filler made by Evolus, the company behind the neurotoxin Jeuveau. It’s designed specifically to restore volume in the mid-face — the cheek and upper cheek area that loses structural support as part of natural aging. Sculpt is built using Cold-X technology, developed by the French biomaterials company Symatese, which is intended to better preserve the natural structure of the HA molecule for results that look and move more naturally than some older filler formulations.
It’s the third product in Evolus’s Evolysse collection. The first two, Evolysse Form and Evolysse Smooth, were FDA-approved in February 2025 and are already available in the U.S. Sculpt is positioned as the “flagship” of the line — Evolus describes it as the most structured product in the collection, purpose-built for a higher-volume correction need than Form or Smooth address.
What the trial data actually showed
Evolus ran a U.S. pivotal study comparing Sculpt directly against Restylane-Lyft, one of the most established fillers used for mid-face volume correction. The study enrolled 304 patients in a multicenter, double-blinded, controlled, non-inferiority design, with patients followed for 24 months — a notably long follow-up period for a filler trial.
The primary goal was simply to show Sculpt performed no worse than Restylane-Lyft. It did better than that: Sculpt demonstrated statistical superiority, with a mean mid-face volume deficit severity score difference of -0.26 (p<0.001) in its favor. On the secondary measure, 90.9% of treated cheeks (389 of 428) in the Sculpt group were rated as treatment responders, compared to 83.3% (110 of 132) for Restylane-Lyft — itself a statistically significant difference (p=0.015). Evolus reported that Sculpt’s safety profile was similar to Restylane’s, with no treatment-related serious adverse events in the study.
Evolus has since submitted the final module of its Premarket Approval application to the FDA. The company anticipates a standard PMA review process, with approval expected in the second half of 2026.
“As an investigator in this pivotal study, I was impressed by the durability of results and high levels of patient satisfaction achieved with Evolysse Sculpt. The product handled exceptionally well during injection, delivering the lift and contouring in the mid-face we seek in daily practice.” — Dr. Gilly Munavalli, MD, MHS, study investigator
The angle worth paying attention to: why a head-to-head win against an established filler matters
Most new filler approvals are measured against placebo or judged only on their own merits. This trial did something more useful for patients trying to decide what’s actually worth waiting for: it ran Sculpt directly against a filler many people have already had injected, in a real comparative head-to-head, not just a “does this work at all” study. A 7.6 percentage point gap in responder rate, with statistical superiority rather than just non-inferiority, is a meaningfully different result than “comparable to existing options” — it’s evidence the new formulation may genuinely outperform one of the category leaders, not just match it.
That’s the detail most coverage of this story has buried under the financial and regulatory framing. For a patient who’s already considered or had Restylane-Lyft for cheek volume, that comparison is the single most relevant piece of information in this entire announcement.
What this means if you’re considering filler for volume loss
Nothing changes for treatment available today — Sculpt isn’t approved yet, and even on an optimistic timeline it likely wouldn’t be commercially available until sometime in 2027. If you’re dealing with mid-face volume loss now, today’s dermal filler options, including Restylane-family products, remain well-studied, effective choices with a long safety track record.
Where this is genuinely useful to know now: if you’re the type of patient who likes to understand what’s coming before deciding when to treat, Sculpt is one to keep an eye on through 2026 and into 2027. It’s also a good reason to bring up timing directly at a consultation — your provider can help you weigh whether to treat now with an established option or whether your specific situation makes sense to revisit once newer formulations reach the market.
Frequently Asked Questions
What is Evolysse Sculpt used for?
Evolysse Sculpt is a hyaluronic acid filler designed to restore volume in the mid-face, addressing the cheek and upper cheek volume loss that comes with natural aging. It is currently under FDA review and is not yet commercially available.
How did Evolysse Sculpt perform compared to Restylane?
In a 304-patient U.S. pivotal trial against Restylane-Lyft, Sculpt showed statistical superiority on the primary efficacy measure (p<0.001) and achieved a 90.9% responder rate compared to 83.3% for Restylane-Lyft, with a similar safety profile and no treatment-related serious adverse events.
When will Evolysse Sculpt be available?
Evolus has submitted its Premarket Approval application to the FDA and anticipates approval in the second half of 2026. Commercial availability would likely follow in early 2027, pending approval and standard launch timelines.
Should I wait for Evolysse Sculpt instead of getting filler now?
Not necessarily. Current FDA-approved fillers for mid-face volume remain well-studied and effective. Whether to treat now or wait depends on your individual goals and timeline, which is best discussed directly with your provider.
Sources: AInvest, August 25, 2025; primary data via Evolus, Inc. press release via StockTitan.
